BD
Therapeutic Areas
Innoviva Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TRELEGY ELLIPTA | Chronic Obstructive Pulmonary Disease (COPD); Asthma | Approved/Commercial |
| ANORO ELLIPTA | Chronic Obstructive Pulmonary Disease (COPD) | Approved/Commercial |
| RELVAR/BREO ELLIPTA | Asthma; COPD | Approved/Commercial |
| AP-PA02 (Lysin PA02) | Pseudomonas aeruginosa infections in cystic fibrosis | Phase 1b/2a |
| AP-SA02 | Staphylococcus aureus bacteremia | Phase 1b/2 |
| Sulbactam-Durlobactam (SUL-DUR) | Infections caused by Acinetobacter baumannii-calcoaceticus complex | Approved |
| Zoliflodacin | Uncomplicated gonorrhea | Phase 3 |
Leadership Team at Innoviva
PR
Pavel Raifeld
Chief Executive Officer
DA
David Altarac
Chief Medical Officer
BE
Bryan E. Roberts
Chairman of the Board
MZ
Marianne Zhen
Chief Accounting Officer
MW
Michael W. Aguiar
Chief Financial Officer
KD
Kostas D. Odysseas
Former Executive Chairman of the Board
GB
George B. Bader
Former Lead Independent Director
SJ
Sarah J. Schlesinger
Independent Director
EE
Elizabeth E. Tallett
Independent Director
MD
Mark DiPaolo
General Counsel & Corporate Secretary